The research was conducted in three Finnish cities with similar baseline COVID-19 incidences between August and September 2021: Helsinki, Turku, and Tampere.
A new document from the Food and Drug Administration (FDA) stated the FDA does not "require demonstration of the prevention of infection or transmission" in order to authorize a vaccine.